178 related articles for article (PubMed ID: 37927116)
21. Combined cemiplimab and radiotherapy for advanced basal cell carcinoma: A case report.
Sarfaraz S; Hayes RC; Hunt AM
SAGE Open Med Case Rep; 2023; 11():2050313X231164248. PubMed ID: 37025249
[TBL] [Abstract][Full Text] [Related]
22. Cemiplimab for locally advanced and metastatic basal cell carcinoma.
Damsin T; Lebas E; Marchal N; Rorive A; Nikkels AF
Expert Rev Anticancer Ther; 2022 Mar; 22(3):243-248. PubMed ID: 35175882
[TBL] [Abstract][Full Text] [Related]
23. Efficacy, safety, and comparison of sonic hedgehog inhibitors in basal cell carcinomas: A systematic review and meta-analysis.
Xie P; Lefrançois P
J Am Acad Dermatol; 2018 Dec; 79(6):1089-1100.e17. PubMed ID: 30003981
[TBL] [Abstract][Full Text] [Related]
24. Systemic Targeted Treatments for Basal Cell Carcinoma.
Svoboda SA; Johnson NM; Phillips MA
Cutis; 2022 Jun; 109(6):E25-E31. PubMed ID: 35960978
[TBL] [Abstract][Full Text] [Related]
25. A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma.
Erdem GU; Sendur MA; Ozdemir NY; Yazıcı O; Zengin N
Curr Med Res Opin; 2015 Apr; 31(4):743-56. PubMed ID: 25690490
[TBL] [Abstract][Full Text] [Related]
26. [Alopecia due to chemotherapeutics, hedgehog inhibitors, targeted antibody therapies and immune checkpoint inhibitors : Pathogenesis, clinical picture, diagnostics and prophylaxis].
Sachse MM; Kähler KC
Dermatologie (Heidelb); 2024 Jun; 75(6):459-465. PubMed ID: 38780777
[TBL] [Abstract][Full Text] [Related]
27. Oral Hedgehog Pathway Inhibition as a Means for Ocular Salvage in Locally Advanced Intraorbital Basal Cell Carcinoma.
Mathis J; Doerr T; Lin E; Ibrahim SF
Dermatol Surg; 2019 Jan; 45(1):17-25. PubMed ID: 30586344
[TBL] [Abstract][Full Text] [Related]
28. Switching Hedgehog inhibitors and other strategies to address resistance when treating advanced basal cell carcinoma.
Doan HQ; Chen L; Nawas Z; Lee HH; Silapunt S; Migden M
Oncotarget; 2021 Sep; 12(20):2089-2100. PubMed ID: 34611482
[TBL] [Abstract][Full Text] [Related]
29. Targeting the Hedgehog Pathway for Locally Advanced and Metastatic Basal Cell Carcinoma.
Yin VT; Esmaeli B
Curr Pharm Des; 2017; 23(4):655-659. PubMed ID: 27928965
[TBL] [Abstract][Full Text] [Related]
30. First reported case of concurrent sonidegib and radiotherapy for recurrent, advanced basal cell carcinoma.
Wang K; Patel M; Prabhu AV; Lewis GD
Rep Pract Oncol Radiother; 2021; 26(1):149-152. PubMed ID: 34046226
[TBL] [Abstract][Full Text] [Related]
31. First-line programmed death-1 inhibitor treatment for locoregionally advanced or metastatic cutaneous squamous cell carcinoma - A real-world experience from Israel.
Averbuch I; Salman S; Shtamper N; Doweck I; Popovtzer A; Markel G; Hendler D; Finkel I; Moore A; Fenig E; Taha T; Mhameed K; Kurman N; Billan S
Front Oncol; 2023; 13():1117804. PubMed ID: 36793605
[TBL] [Abstract][Full Text] [Related]
32. Targeting EGFR and sonic hedgehog pathways for locally advanced eyelid and periocular carcinomas.
Yin VT; Merritt H; Esmaeli B
World J Clin Cases; 2014 Sep; 2(9):432-8. PubMed ID: 25232546
[TBL] [Abstract][Full Text] [Related]
33. New Emerging Treatment Options for Advanced Basal Cell Carcinoma and Squamous Cell Carcinoma.
Villani A; Potestio L; Fabbrocini G; Scalvenzi M
Adv Ther; 2022 Mar; 39(3):1164-1178. PubMed ID: 35089534
[TBL] [Abstract][Full Text] [Related]
34. Tolerance of sonidegib after intolerance of vismodegib-Experience in two patients with nevoid basal cell carcinoma syndrome (Gorlin syndrome).
Venturi F; Trane L; Silvestri F; Zuccaro B; Magnaterra E; De Giorgi V
Skin Health Dis; 2023 Oct; 3(5):e260. PubMed ID: 37799353
[TBL] [Abstract][Full Text] [Related]
35. Update on the anti-programmed cell death-1 receptor antibodies in advanced cutaneous squamous-cell carcinoma.
Benzaquen M
Dermatol Ther; 2020 May; 33(3):e13325. PubMed ID: 32208547
[TBL] [Abstract][Full Text] [Related]
36. Hedgehog Pathway Inhibition for the Treatment of Basal Cell Carcinoma.
Gutzmer R; Solomon JA
Target Oncol; 2019 Jun; 14(3):253-267. PubMed ID: 31243642
[TBL] [Abstract][Full Text] [Related]
37. Using drug scheduling to manage adverse events associated with hedgehog pathway inhibitors for basal cell carcinoma.
Lear JT; Dummer R; Guminski A
Oncotarget; 2021 Dec; 12(26):2531-2540. PubMed ID: 34966484
[TBL] [Abstract][Full Text] [Related]
38. Sonidegib for the Treatment of Advanced Basal Cell Carcinoma.
Brancaccio G; Pea F; Moscarella E; Argenziano G
Front Oncol; 2020; 10():582866. PubMed ID: 33194718
[TBL] [Abstract][Full Text] [Related]
39. Key Clinical Adverse Events in Patients with Advanced Basal Cell Carcinoma Treated with Sonidegib or Vismodegib: A Post Hoc Analysis.
Gutzmer R; Loquai C; Robert C; Dréno B; Guminski A; Lewis K; Arntz R; Martelli S; Squittieri N; Kheterpal M
Dermatol Ther (Heidelb); 2021 Oct; 11(5):1839-1849. PubMed ID: 34490549
[TBL] [Abstract][Full Text] [Related]
40. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment-Update 2023.
Stratigos AJ; Garbe C; Dessinioti C; Lebbe C; van Akkooi A; Bataille V; Bastholt L; Dreno B; Dummer R; Fargnoli MC; Forsea AM; Harwood CA; Hauschild A; Hoeller C; Kandolf-Sekulovic L; Kaufmann R; Kelleners-Smeets NW; Lallas A; Leiter U; Malvehy J; Del Marmol V; Moreno-Ramirez D; Pellacani G; Peris K; Saiag P; Tagliaferri L; Trakatelli M; Ioannides D; Vieira R; Zalaudek I; Arenberger P; Eggermont AMM; Röcken M; Grob JJ; Lorigan P;
Eur J Cancer; 2023 Nov; 193():113252. PubMed ID: 37708630
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
